NASDAQ : TXMD
TherapeuticsMD, Inc. — Key statistics
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Last price 1.83 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 21.18M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 20.83M |
| Enterprise Value | 17.20M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 11.57M |
| Shares Outstanding | 11.57M |
| Shares Change (YoY) | +0.23% |
| Shares Change (QoQ) | +0.03% |
| Owned by Insiders (%) | 2.20% |
| Owned by Institutions (%) | 22.72% |
| Float | 9.49M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.37 |
| Forward PS | n/a |
| PB Ratio | 0.77 |
| P/TBV Ratio | 0.88 |
| P/FCF Ratio | 6.68 |
| P/OCF Ratio | 6.68 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 5.26 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 5.51 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.22 |
| Quick Ratio | 2.65 |
| Debt / Equity | 0.20 |
| Debt / EBITDA | n/a |
| Debt / FCF | 1.78 |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -1.08% |
| Return on Assets (ROA) | -2.88% |
| Return on Invested Capital (ROIC) | -7.31% |
| Return on Capital Employed (ROCE) | -5.38% |
| Weighted Average Cost of Capital (WACC) | 6.17% |
| Revenue Per Employee | $3.27M |
| Profits Per Employee | -$217,000 |
| Employee Count | 1 |
| Asset Turnover | 0.09 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 32,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.65 |
| 52-Week Price Change | +48.76% |
| 50-Day Moving Average | 2.05 |
| 200-Day Moving Average | 2.12 |
| Relative Strength Index (RSI) | 33.35 |
| Average Volume (20 Days) | 20,000 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 24,664 |
| Short Previous Month | 23,663 |
| Short % of Shares Out | 0.21% |
| Short % of Float | 0.26% |
| Short Ratio (days to cover) | 1.40 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 3.27M |
| Gross Profit | 3.27M |
| Operating Income | -1.75M |
| Pretax Income | -263,000 |
| Net Income | -217,000 |
| EBITDA | -1.37M |
| EBIT | -1.75M |
| Loss Per Share | -$0.02 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 9.19M |
| Total Debt | 5.56M |
| Net Cash | 3.63M |
| Net Cash Per Share | $0.31 |
| Equity (Book Value) | 27.13M |
| Book Value Per Share | 2.34 |
| Working Capital | 11.12M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 3.12M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 382,000 |
| Net Borrowing | n/a |
| Free Cash Flow | 3.12M |
| FCF Per Share | $0.27 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -53.55% |
| Pretax Margin | -8.04% |
| Profit Margin | -6.64% |
| EBITDA Margin | -41.87% |
| EBIT Margin | -53.55% |
| FCF Margin | 95.41% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.23% |
| Shareholder Yield | -0.23% |
| Earnings Yield | -1.28% |
| FCF Yield | 14.98% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 47.51% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | May 9, 2022 |
| Split Type | Reverse |
| Split Ratio | 1:50 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -34.09 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |